GLP-1 Market
LLY $1382.75 ▼ -2.3% NVO $39.43 ▼ -3.1% PFE $28.06 ▼ -1.4% VKTX $26.17 ▼ -2.6% KLRA $11.79 ▼ -3.4% GPCR $17.36 ▼ -4.5% RHHBY $59.52 ▼ -1.2%
Market data delayed up to 20 min · Source: Twelve Data
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

DNL343

DNL343

Company
Merit E. Cudkowicz, MD
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Nov 19, 2026

Trial details
  • Completed NCT NCT04268784

    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL343 in Healthy Volunteers

    Not yet reported Denali Therapeutics Inc. 96 participants Est. completion 2021-08-03 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Active, not recruiting NCT NCT04297683

    HEALEY ALS Platform Trial - Master Protocol

    Not yet reported, Not yet reported Merit E. Cudkowicz, MD 1500 participants Est. completion 2028-08 81 sites Stand-alone
    Other conditions: Amyotrophic Lateral Sclerosis
    View official trial listing →
  • Completed NCT NCT04581772

    A Study to Evaluate the Bioavailability and Safety of DNL343 in Healthy Volunteers

    Not yet reported Denali Therapeutics Inc. 31 participants Est. completion 2021-06-04 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT05006352

    A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis

    Not yet reported Denali Therapeutics Inc. 29 participants Est. completion 2024-06-05 7 sites Stand-alone
    Other conditions: Amyotrophic Lateral Sclerosis
    View official trial listing →
  • Completed NCT NCT05842941

    HEALEY ALS Platform Trial - Regimen G DNL343

    Not yet reported, Not yet reported Merit E. Cudkowicz, MD 249 participants Est. completion 2024-10-29 1 site Stand-alone
    Other conditions: Amyotrophic Lateral Sclerosis
    View official trial listing →
  • Completed NCT NCT06281158

    A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants

    Not yet reported Denali Therapeutics Inc. 7 participants Est. completion 2024-04-30 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.